Overview

Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients

Status:
Not yet recruiting

Trial end date:
2027-03-30

Target enrollment:

Participant gender:

Summary

We propose a regimen of six months neoadjuvant lenvatinib in combination with transcatheter arterial chemoembolization (TACE) prior to liver transplantation in patients with hepatocellular carcinoma (HCC) beyond Milan Criteria. Clinical, outcomes, and exploratory data will be compared to a matched, retrospective cohort.

Phase:

Phase 2

Details

Lead Sponsor:

The Methodist Hospital Research Institute

Collaborator:

Eisai Inc.

Treatments:

Lenvatinib